Editorial: Mycobacterial Glycolipids—Role in Immunomodulation and Targets for Vaccine Development

• Gunilla Källenius,
• Jérôme Nigou,
• Andrea Cooper,
• Margarida Correia-Neves,
• Margarida Correia-Neves,
• Margarida Correia-Neves

Affiliations

Gunilla Källenius

Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

Jérôme Nigou

Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, Centre national de la recherche scientifique (CNRS), Université Paul Sabatier, Toulouse, France

Andrea Cooper

Leicester Tuberculosis Research Group (LTBRG), Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom

Margarida Correia-Neves

Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

Margarida Correia-Neves

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal

Margarida Correia-Neves

ICVS/Biomaterials, Biodegradables and Biomimetics (3B’s), Portugal (PT) Government Associate Laboratory, Braga, Portugal